Global Lysosomal Disease Treatment Market is Estimated to Reach $8 Billion by 2024, Says Accurize Market Research
Global Lysosomal Disease Treatment Market report published by Accurize Market Research forecast that the global market is expected to reach $8 billion by 2024; growing at a CAGR of 8.4% from 2017 to 2025. By geography, Asia Pacific and North America are expected to grow at a CAGR of XX% and XX%, respectively, during the forecast period.
To browse the complete report, visit at https://www.accurizemarketresearch.com/report/lysosomal-disease-treatment-market
Increasing diagnosis proportion due to growing awareness and financial inducements for orphan drug improvement to recover R&D expendituresto drive the growth of the market
Increasing diagnosis proportion owed to growing awareness and financial inducements for orphan drug improvement to recover R&D expendituresfuelsthe demand for the global lysosomal disease treatment market. Furthermore, earlier uptake and quicker market access, premium product rating, and growing focus of pharmaceutical companies in the research and development of medications for the treatment of rare diseases also boosts the growth of the market.
Market Segmentation
The global lysosomal disease treatment market has been bifurcated on the basis ofdisease type, route of administration, end use, treatment type and geography. Disease type segment is bifurcated asgauchers, fabry disease, pompe disease, mucopolysaccharidosis (mps) and others. Route of administration includes oral route of administration and intravenous route of administration. Further, end use segment includes hospitals, clinics and others. Treatment type segment is categorized into enzyme replacement therapy market and substrate reduction therapy. By geography the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW).
Top players in the market
The key players operational in the market includes Actelion Pharmaceuticals Ltd., Amicus Therapeutics, Arena Pharmaceuticals Inc., AstellasPharma, Astrazeneca, Biomarin Pharmaceutical Inc., Eli Lilly And Company, Lexicon Pharmaceuticals Inc., Merck & Co. Inc., Novo Nordisk A/S, Sangamo Therapeutics Inc., Sanofi Genzyme and Shire among others.
Contact Us
Stephen Jones,
Head - Sales
Accurize Market Research
K-129, PC COLONY, HANUMAN NAGAR,
KANKARBAGH, PATNA,
Tel: +91-612-2369997